Jan Oscarsson - Concepedia

Author

Jan Oscarsson

Also Known As

Frankel, Robert, J Oscarsson, J. OSCARSSON, J. Oscarsson, JAN OSCARSSON, Jan Oscarsson, Kosiborod, Mikhail, Kosiborod, Mikhail N, Oscarsson, J., Oscarsson, Jan

208

Publications

8.7K

Citations

H-Index

139

Concepts

All Affiliations

University of Gothenburg AstraZeneca (Sweden)Sahlgrenska University Hospital AstraZeneca (United States)Uppsala University

About

Jan Oscarsson is an author at University of Gothenburg specializing in medicine, metabolism, and health sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	46	2.8K
2	Health Sciences	25	34	2.1K
3	Engineering	7	7	141
4	Management	4	4	57
5	Natural Sciences	2	2	53

Jan Oscarsson

116

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
Peripheral Infusion of IGF-I Selectively Induces Neurogenesis in the Adult Rat Hippocampus Maria Åberg, N. David Åberg, Helena Hedbäcker, Journal of Neuroscience	2000	848
Increased Gut Permeability and Microbiota Change Associate with Mesenteric Fat Inflammation and Metabolic Dysfunction in Diet-Induced Obese Mice Yan Y. Lam, Connie Ha, Craig Campbell, PLoS ONE	2012	597
Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study Jan W. Eriksson, Per Lundkvist, Per‐Anders Jansson, Diabetologia	2018	368
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study Rajaa Nahra, Tao Wang, Kishore M. Gadde, Diabetes Care	2021	295
Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet Mikael Bjursell, Therése Admyre, Melker Göransson, American Journal of Physiology-Endocrinology and Metabolism NutritionFfar2-ko MiceMetabolic DisorderGlucose ControlHigh-fat Diet	2010	292
Opposing Effects of Adiponectin Receptors 1 and 2 on Energy Metabolism Mikael Bjursell, Andrea Ahnmark, Mohammad Bohlooly‐Y, Diabetes Metabolic DisorderObesityMetabolic SyndromeMetabolic StateHealth Sciences	2007	276
The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients Aino Latva‐Rasku, Miikka‐Juhani Honka, Joel Kullberg, Diabetes Care	2019	235
Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial Mikhail Kosiborod, Russell Esterline, Remo H.M. Furtado, The Lancet Diabetes & Endocrinology Cardiovascular DiseaseCardiometabolic RiskCardiovascular PharmacologyRiskCardiometabolic Risk Factors	2021	235
Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. S Edén, O. Wiklund, Jan Oscarsson, Arteriosclerosis and Thrombosis A Journal of Vascular Biology Marked IncreaseMetabolic SyndromeHigh DensityPituitary TumorsPituitary Gland	1993	217
Effects of dietary fat profile on gut permeability and microbiota and their relationships with metabolic changes in mice Yan Y. Lam, Connie Ha, Jenny Hoffmann, Obesity	2015	215

Page 1